MIRAMAR, FL, Aug. 25, 2022 (GLOBE NEWSWIRE) — Stemtech Corporation (“Stemtech”) (OTCQB: STEK), an innovative nutraceutical company and a pioneer in the field of stem cell nutrition, today announced that it has sponsored ADVENT EXPO.
Stemtech Corporation President and COO, John W. Meyer, says that “Stemtech Corporation is excited to become a sponsor of ADVENT EXPO as it has become a central meeting place and center for important social interactions. Advent Expo’s underlying technology enables consumers and large enterprises access to a virtual EXPO in the metaverse. Such a platform provides tremendous exposure for Stemtech to be introduced to so many people who are looking for anti-aging, all-natural plant-based stem cell nutrition products, as well as an income earning opportunity.” Henry Val of Advent Expo commented that “the Expo has millions of viewers all around the world who are seeking to find opportunities to make a connection where health and finances are key, for Stemtech we believe we can add More Sales+More Leads + Avatars that Talk Like A Real Person +More Team Members.”
About ADVENT GALAXY Inc. and its main product ADVENT EXPO: Expo is going to become a central meeting place and center for important social interactions between people of different backgrounds and age groups. Underlying technology allows for merchants, consumers, and large enterprises to be replaced by a virtual EXPO in the metaverse. EXPO will cater to B2C+B2B+B2E= B2X, or simply stated B2All. Entertainment zones, meeting and interacting with your friends at a coffee shop in real time is the future. Conducting business in co-working spaces without leaving one’s house is the future.
About Stemtech Corporation
Stemtech Corporation, a leading nutraceutical company with a direct sales distribution model, was founded on April 18, 2018, after acquiring the operations from its predecessor Stemtech International, Inc. which was founded in 2005. From 2010 through 2015, Stemtech International, Inc., was recognized four separate times on the Inc. 5000 Fastest-Growing Companies list. In 2018, the Company underwent an extensive executive reorganization, and continued operations under new leadership. Stemtech specializes in creating products and formulas that are patent protected in the U.S. and in select international markets. The Company’s patented formulas help the release, circulation and migration of the body’s adult stem cells from its bone marrow. The Company markets its products under the following brands: RCM System, stemrelease3™, Stemflo® MigraStem, OraStem® (Oral Health Care), and D-Fuze™ (EMF blocker). Its nutraceutical products are all-natural, plant-based and manufactured under cGMP (Current Good Manufacturing Practices) under the auspices of the Dietary Supplement Health and Education Act (DSHEA). For more information, please visit www.stemtech.com.
This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements identified by words such as “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “targets,” “projects” and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-Q Report filed on August 23, 2022. We undertake no duty to update any forward-looking statement, or any information contained in this press release or in other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Stemtech Corporation which are condoned by the Company must emanate from the Company itself and bear our name as its Source.
Frank J. Pena, 908 675-0581
The content is by GlobeNewswire. DKODING Media is not responsible for the content provided or any links related to this content. DKODING Media is not responsible for the correctness, topicality or the quality of the content.